Having trouble accessing articles? Reset your cache.

VP20621: Phase II data

A double-blind, international Phase II trial in 168 patients previously treated for CDI with oral vancomycin or metronidazole showed that all doses of once-daily VP20621 met the primary endpoint of increasing the proportion of patients with non-toxigenic C. difficile detected in stool during the 14-day

Read the full 450 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers